Literature DB >> 3058816

Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation.

M Ellis1, S Gupta, S Galant, S Hakim, C VandeVen, C Toy, M S Cairo.   

Abstract

We measured the neutrophil function of 6 patients with AIDS and Kaposi's sarcoma (KS); 22 patients with AIDS-related complex (ARC); and 28 healthy, heterosexual controls. Neutrophils from patients with ARC showed significantly less chemotaxis (P less than or equal to .025) than did those from patients with AIDS and KS or from controls. Serum from patients with AIDS and KS or with ARC significantly (P less than or equal to .05) inhibited chemotaxis of neutrophils from controls; heat treatment of the serum abolished this inhibitory effect. Bacterial killing by neutrophils from patients with AIDS and KS or with ARC was also significantly (P less than or equal to .05) less than for neutrophils from controls, as was neutrophil phagocytosis binding of Candida albicans (P less than or equal to .05). Expression of OKM1 antigen was increased in the patients studied. Enzyme degranulation, adherence, and aggregation were also examined. The defects found in neutrophil function are selective and may be important in the increased susceptibility of patients with human immunodeficiency virus infection to bacterial and fungal infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3058816     DOI: 10.1093/infdis/158.6.1268

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Mononuclear cells from HIV-infected patients produce factors which enhance functional activity of polymorphonuclear neutrophils from healthy subjects.

Authors:  D I Gabrilovich; G K Shepeleva; L V Serebrovskaya; L A Avdeeva; Z K Suvorova; I M Rosly; V K Oganezov; M Z Saidov; A V Panyutich; V V Pokrovsky
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus in the patient with HIV infection.

Authors:  Kathy Thompson; Francesca Torriani
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

4.  No effect of a 30-h period of sleep deprivation on leukocyte trafficking, neutrophil degranulation and saliva IgA responses to exercise.

Authors:  J S Costa Ricardo; Louise Cartner; Samuel J Oliver; Stewart J Laing; Robert Walters; James L J Bilzon; Neil P Walsh
Journal:  Eur J Appl Physiol       Date:  2008-11-19       Impact factor: 3.078

5.  Mathematical analysis of cell-target encounter rates in three dimensions. Effect of chemotaxis.

Authors:  S B Charnick; D A Lauffenburger
Journal:  Biophys J       Date:  1990-05       Impact factor: 4.033

Review 6.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Impaired macrophage phagocytosis of apoptotic neutrophils in patients with human immunodeficiency virus type 1 infection.

Authors:  Donato Torre; Luisa Gennero; F M Baccino; Filippo Speranza; Gilberto Biondi; Agostino Pugliese
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 8.  Should patients positive for HIV infection receive pneumococcal vaccine?

Authors:  A Jain; S Jain; V Gant
Journal:  BMJ       Date:  1995-04-22

Review 9.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 10.  Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.

Authors:  J W Tappero; B A Perkins; J D Wenger; T G Berger
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.